FORM 3

UNITED STATES SECURITIES AND EXCHANGE **COMMISSION**

Washington, D.C. 20549

OMB APPROVAL 3235-0104 OMB Number: Estimated average burden hours per response:

0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

					16(a) of the Securities Exe f the Investment Company			1934				
1. Name and Address of Reporting Person* ORBIMED ADVISORS LLC			l Requirin	g Statement Day/Year)	3. Issuer Name and Ticker or Trading Symbol Oric Pharmaceuticals, Inc. [ORIC]							
(Last) (First) (Middle) 601 LEXINGTON AVENUE					4. Relationship of Repolssuer (Check all applicable)	J				Amendment, d (Month/Day	Date of Original 'Year)	
(Street) NEW YORK	NY	10022			X Director Officer (give title below)	X		(specify		Form filed Person	by One Reporting by More than One	
(City)	(State)	(Zip)										
			Table I - N	on-Deriva	tive Securities Ben	eficia	ally O	wned				
1. Title of Security (Instr. 4)				2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		Direct ndirect	4. Nature of Indirect Beneficial Ownership (Instr. 5)					
		(e			re Securities Benefi ants, options, conv)			
Exp		2. Date Exerc Expiration Da (Month/Day/\	ate	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)			4. Conversion or Exercise		5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr.		
			Date Exercisable	Expiration Date	Title		ount or ober of res	Price of Derivati Securit	vative or Indirect		5)	
Series B Pre	eferred Stock		(1)	(1)	Common Stock	1,87	75,000	(1)		I	See footnote ⁽²⁾⁽³⁾	
Series C Pre	eferred Stock		(1)	(1)	Common Stock	373	3,356	(1)		I	See footnote ⁽²⁾⁽³⁾	
Series D Pro	eferred Stock		(1)	(1)	Common Stock	23	6,111	(1)		I	See footnote ⁽²⁾⁽³⁾	
	Address of Repo	ū										

(Street) **NEW YORK** NY 10022 (City) (State) (Zip) 1. Name and Address of Reporting Person* OrbiMed Capital GP VI LLC (Middle) (Last) (First) **601 LEXINGTON AVENUE** 54TH FLOOR (Street) **NEW YORK** NY 10022

(City)	(State)	(Zip)	
--------	---------	-------	--

Explanation of Responses:

- 1. Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date.
- 2. The shares are held of record by by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors LLC ("Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI.
- 3. This report on Form 3 is jointly filed by Advisors and GP VI. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated a representative, Carl L. Gordon ("Gordon"), a member of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.

Remarks:

OrbiMed Advisors LLC,

By: /s/ Douglas Coon, 04/23/2020

Chief Compliance Officer

OrbiMed Capital GP VI

LLC, By: /s/ Douglas

Coon, Chief Compliance

Officer

** Signature of Reporting

Date

04/23/2020

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.